Raloxifene
Treatment for Osteoporosis
Typical Dosage: 60 mg orally once daily
Effectiveness
45%
Safety Score
60%
Clinical Trials
35
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
60 mg orally once daily
Time to Effect
6-12 months
Treatment Duration
Long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$250
Side Effect Mgmt:$50
Total Annual:$450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.08
Raloxifene Outcomes
for Osteoporosis
Efficacy Outcomes
Overall Effectiveness
+45%
Common Side Effects
Hot flashes
+20%
Leg cramps
+8%
Peripheral edema
+7%
Venous thromboembolism (DVT, PE)
+2%
Active Clinical Trials
1 active trial recruiting for Raloxifene in Osteoporosis
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
NCT03623633ACTIVE NOT RECRUITINGPHASE4
51 participants
INTERVENTIONAL
Boston, United States
Started: Nov 30, 2018
Completed Clinical Trials
16 completed trials for Raloxifene in Osteoporosis
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
NCT00670319COMPLETEDPHASE3
7.71K participants
INTERVENTIONAL
San Francisco, United States +24 more
Started: Nov 1, 1994
Long Term Effects of Raloxifene Treatment on Bone Quality
NCT00532428COMPLETEDPHASE4
31 participants
INTERVENTIONAL
Indianapolis, United States +6 more
Started: Apr 1, 2003
Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
NCT01166958COMPLETEDPHASE4
26 participants
INTERVENTIONAL
Madison, United States
Started: Sep 1, 2010
Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy
NCT00371956COMPLETEDPHASE4
114 participants
INTERVENTIONAL
Hong Kong, China
Started: Sep 1, 2006
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
NCT00383422COMPLETEDPHASE3
320 participants
INTERVENTIONAL
Gainesville, United States +20 more
Started: Oct 1, 2006
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
NCT00163137COMPLETEDPHASE3
540 participants
INTERVENTIONAL
Albany, United States +71 more
Started: May 1, 2003
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
NCT00532246COMPLETEDPHASE4
147 participants
INTERVENTIONAL
La Jolla, United States +4 more
Started: Mar 1, 2003
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
NCT00191425COMPLETEDPHASE4
810 participants
INTERVENTIONAL
Bad Pyrmont, Germany
Started: Aug 1, 2002
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
NCT04736693COMPLETED
18K participants
OBSERVATIONAL
Boston, United States
Started: Sep 22, 2020
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
NCT00035256COMPLETEDPHASE4
330 participants
INTERVENTIONAL
Maywood, United States +4 more
Started: Oct 1, 2001
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
NCT03764462COMPLETEDPHASE1
52 participants
INTERVENTIONAL
Daegu, South Korea
Started: Dec 14, 2018
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
NCT01544894COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Valencia, Spain
Started: Sep 1, 2009
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00079924COMPLETEDPHASE4
200 participants
INTERVENTIONAL
Birmingham, United States +9 more
Started: Nov 1, 2004
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
NCT03824171COMPLETEDPHASE1
52 participants
INTERVENTIONAL
Seoul, South Korea
Started: Feb 28, 2019
Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
NCT01416194COMPLETED
10.5K participants
OBSERVATIONAL
Started: Jul 25, 2011
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
NCT00046137COMPLETEDPHASE3
INTERVENTIONAL
Anaheim, United States +12 more
Showing 20 of 35 total trials